Isolation of Four Pepsin-Like Protease Genes from Aspergillus Niger and Analysis of the Effect of Disruptions on Heterologous Laccase Expression

Total Page:16

File Type:pdf, Size:1020Kb

Isolation of Four Pepsin-Like Protease Genes from Aspergillus Niger and Analysis of the Effect of Disruptions on Heterologous Laccase Expression Available online at www.sciencedirect.com Fungal Genetics and Biology 45 (2008) 17–27 www.elsevier.com/locate/yfgbi Isolation of four pepsin-like protease genes from Aspergillus niger and analysis of the effect of disruptions on heterologous laccase expression Yongchao Wang a, Wei Xue a, Andrew H. Sims b, Chuntian Zhao a, Aoquan Wang a,*, Guomin Tang a, Junchuan Qin c, Huaming Wang b a Key Laboratory of Systematic Mycology and Lichenology, Institute of Microbiology, Chinese Academy of Sciences, 100101 Beijing, PR China b Genencor, A Danisco Division, Palo Alto, CA 94304, USA c School of Life Science, Nanjing University, 210093 Nanjing, PR China Received 10 February 2007; accepted 24 September 2007 Available online 29 September 2007 Abstract Four new aspartic protease genes pepAa, pepAb, pepAc and pepAd from Aspergillus niger were identified using a comparative genomic approach. All four gene products have highly conserved attributes that are characteristic of aspartic proteases; however, each one has novel sequence features. The PEPAa protease appears to represent an ortholog of a pepsin-type aspartic protease previously identified from Talaromyces emersonii and Scleotinia sclerotiorum. The PEPAb protease appears to be an ortholog of an aspartic protease previ- ously identified from BcAP1 of Botryotinia fuckeliana. The PEPAc protease also appears to be an ortholog of BcAP5 from B. fuckeliana. These four genes appear to be conserved in many species of filamentous fungi, all except PEPAb contain a predicted signal peptide. Tran- scriptome analysis revealed that transcripts of the pepAa gene of Aspergillus nidulans were significantly up-regulated due to recombinant chymosin secretion, suggesting that silencing these genes may lead to improved yields of secreted proteins. To establish the effects of reduced protease activity on the stabilities of secreted proteins, three of the four genes were individually disrupted by double crossover, although we were unable to disrupt the pepAc gene. The secretion level of heterologous laccase in the pepAa, pepAb and pepAd disruption mutants were increased by about 21%, 42% and 30%, respectively. And their total glucogenic enzymes secretion were also increased by about 18.7%, 37.0% and 5.20%, respectively. Ó 2007 Elsevier Inc. All rights reserved. Keywords: Aspergillus niger; Pepsin-like protease; Disruption; Heterologous laccase expression 1. Introduction tein production upon deletion of the protease genes (Archer et al., 1992; van den Hombergh et al., 1997b). Filamentous fungi represent excellent hosts for secre- Four extracellular proteases with acid pH optima (an tion of homologous and heterologous proteins (Conesa aspartic protease, PEPA, a glutamic protease, PEPB and et al., 2001). However, proteolytic degradation is a major two serine carboxypeptidases, PEPF and PEPG) have pre- problem during protein production even in a well-estab- viously been characterized (Berka et al., 1990; Inoue lished organism such as Aspergillus niger (Archer et al., et al., 1991; Krishnan and Vijayalakshimi, 1985; Mattern 1992). Proteolytic degradation affects mainly heterologous et al., 1992; van den Hombergh et al., 1994). A fifth pro- proteins evidenced by improvement of heterologous pro- tease gene, encoding an extracellular subtilisin-type serine protease, PEPD, has been cloned based on conserved * Corresponding author. Fax: +86 010 64807505. amino acid sequences within subtilisins (Jarai et al., E-mail address: [email protected] (A. Wang). 1994a). Furthermore, three proteases that are homologous 1087-1845/$ - see front matter Ó 2007 Elsevier Inc. All rights reserved. doi:10.1016/j.fgb.2007.09.012 18 Y. Wang et al. / Fungal Genetics and Biology 45 (2008) 17–27 to yeast vacuolar proteases have been cloned from A. 2. Materials and methods niger; these are PEPE, a pepsin-type aspartyl endopro- tease that is the homologue of the vacuolar pep4 gene 2.1. Strains and growth conditions product in yeast (Jarai et al., 1994b), PEPC, a subtilisin- type serine endoprotease (Frederick et al., 1993) and A. niger GICC2773 (Valkonen et al., 2003) was used for CPY, a serine carboxypeptidase (Yaver et al., 1995). Fol- the disruption experiments of the putative aspartic protease lowing the whole-genome sequencing of A. niger (Pel genes. This strain contains the disruption mutant of the et al., 2007), approximately 200 predicted proteases have pepA gene and integrated heterologous gene (lcc1 of been identified, with similar numbers also seen following theTrametes versicolor laccase gene) expressed as fusion whole-genome sequencing of Aspergillus nidulans (Gala- to the glucoamylase. Escherichia coli DH5a served as host gan et al., 2005), Aspergillus oryzae (Machida et al., for routine DNA manipulations (Sambrook et al., 1989). 2005) and Aspergillus fumigatus (Nierman et al., 2005). Aspergillus niger GICC2773 strains were maintained on Pepsin-like enzymes such as aspartic proteases are solid sporulation medium, GMP (2% glucose, 2% maltose members of the A1 family of peptidases (Rawlings extract, 0.1% peptone, 1% agar) supplemented with 0.3% et al., 2004). This family comprises proteins with a casein when necessary. Disruption mutants were grown three-dimensional structure close to that of pepsin. Gen- on GMP supplemented with 200 lg hygromycin B per erally, these enzymes form two domains with different ml. Seed cultures of the A. niger strains in 30 ml of S3Y2 amino acid sequences, but basically similar folds. The medium (3% soluble starch, 2% yeast extracts, 0.5% catalytic site of the pepsin-like enzymes is formed at KH2PO4, 0.5% corn powder) were incubated at 30 °C with the junction of the two domains. It contains two aspartic 200 rpm agitation in a rotary G10 incubator (New Bruns- acid residues, Asp32 and Asp215 (human pepsin number- wick Scientific, NJ) for 14 h. For laccase production study, ing), one in each domain (Blundell et al., 1998). In accor- A. niger strains were grown in 30 ml of modified Promosoy dance with the accepted mechanism of the pepsin-like medium (Ward et al., 2004), where the promosoy was enzyme function (James, 2004), the Asp215 has to be substituted with tryptic soy broth (Difco, Detroit, MI). charged, whereas Asp32 has to be protonated. A remark- able property of the catalytic center is its adaptation for 2.2. Protease identification and sequence analysis the action in a wide range of pH, from 4.0 to 7.0. Aspar- tic proteinases have been identified from Botrystis cinerea The predicted pepsin-like proteases were identified as (ten Have et al., 2004) and A. oryzae (Machida et al., described previously (Sims et al., 2004a,b). Briefly, files 2005). containing all the predicted open reading frames (ORFs) Berka et al. showed that deletion of the pepA gene from species of filamentous fungi with recently completed increased bovine prochymosin production by more than whole-genome sequences (Table 2) were downloaded 66% (Berka et al., 1990). Van den Hombergh et al. dis- from their respective databases and filtered for sequences rupted three different acid-protease genes in A. niger, of 100 or more amino acids beginning with a methionine pepA, pepB and pepE, to determine the contribution of start codon. These were then searched for putative aspar- each protease to the overall protease spectrum using tic protease domains (PF00026) using the protein families bovine serum albumin as a broad substrate. They con- and HMM database (Pfam) release 11.0 (Bateman et al., cluded that the PEPA and PEPB proteases appeared to 2004). The results were compared to known protease constitute 84% and 6% of the extracellular acidic proteo- families in the peptidase database, MEROPS release 6.4 lytic activity, respectively, whereas the PEPE protease is (Rawlings et al., 2004). The coding sequences for pre- responsible for 68% of the intracellular acidic protease dicted proteases were manually compared using the Clu- activity (van den Hombergh et al., 1997a). Moralejo stalW program (Thompson et al., 1994) with default et al. also showed that a defect in the pepA gene reduced settings. Additional sequences of genes from other spe- degradation of overexpressed thaumatin in A. niger cies that have previously been cloned and characterized (Moralejo et al., 2000). were added to demonstrate that the ORFs represent Here, we report the isolation and characterization of putative orthologs of known genes. The Treeview pro- four ‘new’ genes (pepAa, pepAb, pepAc and pepAd) gram was used to draw and visualize hierarchical trees encoding pepsin-like aspartic proteases from A. niger based upon amino acid sequence alignments (Page, and demonstrate that these genes are conserved within 1996). The SignalP (Nielsen et al., 1997) and ProP the Aspergillus genus. The proteins possess different char- (Duckert et al., 2004) programs were used to identify acteristics and may have distinct localizations and func- prepro signal sequences and propeptide cleavage sites, tions. Transcription of the pepAa gene during respectively. The big-PI (http://mendel.imp.univie.ac.at/ recombinant protein production was observed with our sat/gpi/fungi_server.html) fungal predictor was also used A. nidulans cDNA microarray (Sims et al., 2005). There- to identify likely GPI modification sites (Eisenhaber fore, we examined the effect of disrupting these proteases et al., 2004). The disulfide bonds were predicted using on the secretion of the homologous and the heterologous DIpro 2.0 (http://contact.ics.uci.edu/bridge.html)(Cheng proteins in A. niger. et al., 2006). Y. Wang et al. / Fungal Genetics and Biology 45 (2008) 17–27 19 2.3. Microarray analysis sequence of the pepAx genes of A. niger. At the 50 end of each primer, a restriction enzyme recognition site of HpaI Transcriptome analysis was performed as described pre- was introduced. The PCR was carried out with Pfu DNA viously (Sims et al., 2005, 2004b,c). Briefly, a pyrG- single- polymerase and consisted of one cycle at 94 °C for 4 min copy recombinant chymosin-producing A. nidulans strain and 30 cycles at 94 °C for 1 min, 55 °C for 1 min, 72 °C (Cullen et al., 1987) was compared to its parental strain for 2.5 min, and then a final extension at 72 °C for transformed with an empty vector.
Recommended publications
  • Functional Characterization of Extracellular Protease Inhibitors of Phytophthora Spp and Their Targets Tomato Proteases
    FUNCTIONAL CHARACTERIZATION OF EXTRACELLULAR PROTEASE INHIBITORS OF PHYTOPHTHORA SPP AND THEIR TARGETS TOMATO PROTEASES DISSERTATION Presented in Partial Fulfillment of the Requirements for The Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Jing Song, M.S. * * * * The Ohio State University 2007 Dissertation Committee: Dr. Sophien Kamoun, Adviser Approved by Dr. Anne E. Dorrance Dr. Terrence L. Graham Adviser Dr. Margaret G. Redinbaugh ______________________ Dr. Eric J. Stockinger Graduate Program in Plant Pathology ABSTRACT The interplay between proteases and protease inhibitors during plant- pathogen interaction represents a common strategy for defense and counter- defense. The plant pathogens Phytophthora infestans and Phytophthora mirabilis secrete effectors such as protease inhibitors that facilitate host colonization through a defense-counterdefense mechanism. The P. infestans serine protease inhibitors EPI1 and EPI10 physically bind and inhibit the tomato serine protease P69B. On the other hand, the P. infestans cysteine protease inhibitor EPIC2B targets PIP1, a papain-like protease that has close similarity to another tomato cysteine protease Rcr3, which is required for the fungal resistance and Avr2 hypersensitivity in Cf-2 tomato. The objective of this research is to characterize these protease inhibitors and their association with specific targets in the host. We studied the structure and activities of these protease inhibitors and their target proteases using recombinant proteins expressed in Escherichia coli and Nicotiana benthamiana. PIP1-His was pulled down using coimmunoprecipitation with anti-FLAG resin from N. benthamiana apoplast by recombinant protein FLAG-EPIC2B, suggesting physical interaction of EPIC2B and PIP1. Similarly, tomato protease Rcr3pim was shown to be a common target for both the ii Cladosporium fulvum effector Avr2 and P.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • De¢Cient Strains of the Methylotrophic Yeast Ogataea Minuta
    RESEARCH ARTICLE Antibody expression in protease-de¢cient strains ofthe methylotrophic yeast Ogataea minuta Kousuke Kuroda1,2, Yoshinori Kitagawa1, Kazuo Kobayashi1, Haruhiko Tsumura1, Toshihiro Komeda3, Eiji Mori4, Kazuhiro Motoki4, Shiro Kataoka4, Yasunori Chiba5 & Yoshifumi Jigami2,5 1Kirin Brewery Co. Ltd, CMC R&D Laboratories, Gunma, Japan; 2Graduate School of Life and Environmental Science, University of Tsukuba, Ibaraki, Japan; 3Kirin Brewery Co. Ltd, Central Laboratories for Frontier Technology, Kanagawa, Japan; 4Kirin Brewery Co. Ltd, Pharmaceutical Research Laboratories, Gunma, Japan; and 5National Institute of Advanced Industrial Science and Technology (AIST), Ibaraki, Japan Downloaded from https://academic.oup.com/femsyr/article/7/8/1307/549124 by guest on 27 September 2021 Correspondence: Yoshifumi Jigami, National Abstract Institute of Advanced Industrial Science and Technology (AIST), Ibaraki 305-8566, Japan. When human antibody genes were expressed in the methylotrophic yeast Ogataea Tel.: 181 29 861 6160; fax: 181 29 861 minuta, the secreted antibody became partially degraded. To suppress the 6161; e-mail: [email protected] degradation, a vacuolar protease-deficient strain was constructed and its antibody production was evaluated. Although antibody productivity was improved in the Received 28 February 2007; revised 28 May vacuolar protease-deficient strain, the secreted antibody still became partially 2007; accepted 16 June 2007. degraded. Peptide sequencing revealed that the cleavage occurred in the CH1 First published online 23 August 2007. region of the heavy chain, implying that the cleavage was caused by an aspartic protease, Yps1p. To inhibit this cleavage, Yps1p-deficient strains were constructed DOI:10.1111/j.1567-1364.2007.00291.x and their antibody production was evaluated.
    [Show full text]
  • Wo 2011/089170 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date _ . _ 28 July 2011 (28.07.2011) WO 2011/089170 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 14/50 (2006.01) A61K 47/48 (2006.01) kind of national protection available): AE, AG, AL, AM, C12P 21/00 (2006.01) A61P 3/04 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 38/18 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/EP201 1/050718 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 20 January 20 11 (20.0 1.20 11) NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (25) Filing Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 12/692,227 22 January 2010 (22.01 .2010) U S GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, PCT/EP20 10/050720 ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, 22 January 2010 (22.01 .2010) EP TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 10165927.4 15 June 2010 (15.06.2010) EP EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, 61/356,086 18 June 2010 (18.06.2010) U S LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (71) Applicant (for all designated States except US): NOVO GW, ML, MR, NE, SN, TD, TG).
    [Show full text]
  • New Human Aspartic Proteinases
    View metadata,FEBS 21271 citation and similar papers at core.ac.uk FEBS Letters 441brought (1998) to you 43^48 by CORE provided by Elsevier - Publisher Connector Napsins: new human aspartic proteinases Distinction between two closely related genes Peter J. Tatnell1;a, David J. Powell1;b, Je¡rey Hilla, Trudi S. Smithb, David G. Tewb, John Kaya;* aSchool of Biosciences, Cardi¡ University, P.O. Box 911, Cardi¡ CF1 3US, UK bSmithKline Beecham Pharmaceuticals, 709 Swedeland Rd, King of Prussia, PA 19406, USA Received 27 October 1998 [6]. With the advent of human genome projects, ready access Abstract cDNA sequences were elucidated for two closely related human genes which encode the precursors of two hitherto to a vast array of human expressed sequence tags (ESTs) is unknown aspartic proteinases. The (pro)napsin A gene is now possible. Interrogation of these databases for the hall- expressed predominantly in lung and kidney and its translation mark sequences of aspartic proteinases, i.e. the VHydro- product is predicted to be a fully functional, glycosylated aspartic phobic-Hydrophobic-Asp-Thr/Ser-GlyV plus VHydropho- proteinase (precursor) containing an RGD motif and an bic-Hydrophobic-GlyV motifs, gave a preliminary additional 18 residues at its C-terminus. The (pro)napsin B indication that yet further aspartic proteinases were encoded gene is transcribed exclusively in cells related to the immune within the human genome. We have called these napsins (for system but lacks an in-frame stop codon and contains a number novel aspartic proteinases of the pepsin family). of polymorphisms, one of which replaces a catalytically crucial Gly residue with an Arg.
    [Show full text]
  • Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases
    Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases Alan J. Barrett Neil D. Rawlings J. Fred Woessner Editor biographies xxi Contributors xxiii Preface xxxi Introduction ' Abbreviations xxxvii ASPARTIC PEPTIDASES Introduction 1 Aspartic peptidases and their clans 3 2 Catalytic pathway of aspartic peptidases 12 Clan AA Family Al 3 Pepsin A 19 4 Pepsin B 28 5 Chymosin 29 6 Cathepsin E 33 7 Gastricsin 38 8 Cathepsin D 43 9 Napsin A 52 10 Renin 54 11 Mouse submandibular renin 62 12 Memapsin 1 64 13 Memapsin 2 66 14 Plasmepsins 70 15 Plasmepsin II 73 16 Tick heme-binding aspartic proteinase 76 17 Phytepsin 77 18 Nepenthesin 85 19 Saccharopepsin 87 20 Neurosporapepsin 90 21 Acrocylindropepsin 9 1 22 Aspergillopepsin I 92 23 Penicillopepsin 99 24 Endothiapepsin 104 25 Rhizopuspepsin 108 26 Mucorpepsin 11 1 27 Polyporopepsin 113 28 Candidapepsin 115 29 Candiparapsin 120 30 Canditropsin 123 31 Syncephapepsin 125 32 Barrierpepsin 126 33 Yapsin 1 128 34 Yapsin 2 132 35 Yapsin A 133 36 Pregnancy-associated glycoproteins 135 37 Pepsin F 137 38 Rhodotorulapepsin 139 39 Cladosporopepsin 140 40 Pycnoporopepsin 141 Family A2 and others 41 Human immunodeficiency virus 1 retropepsin 144 42 Human immunodeficiency virus 2 retropepsin 154 43 Simian immunodeficiency virus retropepsin 158 44 Equine infectious anemia virus retropepsin 160 45 Rous sarcoma virus retropepsin and avian myeloblastosis virus retropepsin 163 46 Human T-cell leukemia virus type I (HTLV-I) retropepsin 166 47 Bovine leukemia virus retropepsin 169 48
    [Show full text]
  • 12) United States Patent (10
    US007635572B2 (12) UnitedO States Patent (10) Patent No.: US 7,635,572 B2 Zhou et al. (45) Date of Patent: Dec. 22, 2009 (54) METHODS FOR CONDUCTING ASSAYS FOR 5,506,121 A 4/1996 Skerra et al. ENZYME ACTIVITY ON PROTEIN 5,510,270 A 4/1996 Fodor et al. MICROARRAYS 5,512,492 A 4/1996 Herron et al. 5,516,635 A 5/1996 Ekins et al. (75) Inventors: Fang X. Zhou, New Haven, CT (US); 5,532,128 A 7/1996 Eggers Barry Schweitzer, Cheshire, CT (US) 5,538,897 A 7/1996 Yates, III et al. s s 5,541,070 A 7/1996 Kauvar (73) Assignee: Life Technologies Corporation, .. S.E. al Carlsbad, CA (US) 5,585,069 A 12/1996 Zanzucchi et al. 5,585,639 A 12/1996 Dorsel et al. (*) Notice: Subject to any disclaimer, the term of this 5,593,838 A 1/1997 Zanzucchi et al. patent is extended or adjusted under 35 5,605,662 A 2f1997 Heller et al. U.S.C. 154(b) by 0 days. 5,620,850 A 4/1997 Bamdad et al. 5,624,711 A 4/1997 Sundberg et al. (21) Appl. No.: 10/865,431 5,627,369 A 5/1997 Vestal et al. 5,629,213 A 5/1997 Kornguth et al. (22) Filed: Jun. 9, 2004 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2005/O118665 A1 Jun. 2, 2005 EP 596421 10, 1993 EP 0619321 12/1994 (51) Int. Cl. EP O664452 7, 1995 CI2O 1/50 (2006.01) EP O818467 1, 1998 (52) U.S.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0120901 A1 Wu Et Al
    US 20040120901A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0120901 A1 Wu et al. (43) Pub. Date: Jun. 24, 2004 (54) DENTAL COMPOSITIONS INCLUDING (22) Filed: Dec. 20, 2002 ENZYMES AND METHODS Publication Classification (76) Inventors: Dong Wu, Woodbury, MN (US); Joel D. Oxman, Minneapolis, MN (US); (51) Int. Cl." ............................... A61K 7/28: A61C 5/00 Sumita B. Mitra, West St. Paul, MN (52) U.S. Cl. ........................................... 424/50; 433/217.1 (US); Ingo Reinhold Haberlein, Weilheim (DE) (57) ABSTRACT A hardenable dental composition that includes a polymer Correspondence Address: izable component and a therapeutic enzyme mixed within 3M INNOVATIVE PROPERTIES COMPANY the polymerizable component, wherein upon hardening the PO BOX 33427 polymerizable component to form a hardened dental mate ST. PAUL, MN 55133-3427 (US) rial having a therapeutic enzyme mixed therein, the hard ened dental material with the enzyme mixed therein is in (21) Appl. No.: 10/327,411 contact with Saliva in a Subject's mouth for at least 1 day. US 2004/O120901 A1 Jun. 24, 2004 DENTAL COMPOSITIONS INCLUDING ENZYMES form a hardened dental material having a therapeutic AND METHODS enzyme mixed therein, the hardened dental material with the enzyme mixed therein is in contact with Saliva in a Subject's BACKGROUND mouth for at least 1 day; wherein the therapeutic enzyme is Selected from the group consisting of oxidases, peroxidases, 0001 Enzymes have been used in products for the laccases, proteases, carbohydrases, lipases, and combina improvement of oral health. Such products include, for tions thereof, and wherein the polymerizable component is example, mouthwashes, toothpastes, dentrifices, and the Selected from the group consisting of (meth)acrylates, like.
    [Show full text]
  • Peptide Sequence
    Peptide Sequence Annotation AADHDG CAS-L1 AAEAISDA M10.005-stromelysin 1 (MMP-3) AAEHDG CAS-L2 AAEYGAEA A01.009-cathepsin D AAGAMFLE M10.007-stromelysin 3 (MMP-11) AAQNASMW A06.001-nodavirus endopeptidase AASGFASP M04.003-vibriolysin ADAHDG CAS-L3 ADAPKGGG M02.006-angiotensin-converting enzyme 2 ADATDG CAS-L5 ADAVMDNP A01.009-cathepsin D ADDPDG CAS-21 ADEPDG CAS-L11 ADETDG CAS-22 ADEVDG CAS-23 ADGKKPSS S01.233-plasmin AEALERMF A01.009-cathepsin D AEEQGVTD C03.007-rhinovirus picornain 3C AETFYVDG A02.001-HIV-1 retropepsin AETWYIDG A02.007-feline immunodeficiency virus retropepsin AFAHDG CAS-L24 AFATDG CAS-25 AFDHDG CAS-L26 AFDTDG CAS-27 AFEHDG CAS-28 AFETDG CAS-29 AFGHDG CAS-30 AFGTDG CAS-31 AFQHDG CAS-32 AFQTDG CAS-33 AFSHDG CAS-L34 AFSTDG CAS-35 AFTHDG CAS-L36 AGERGFFY Insulin B-chain AGLQRGGG M14.004-carboxypeptidase N AGSHLVEA Insulin B-chain AIDIDG CAS-L37 AIDPDG CAS-38 AIDTDG CAS-39 AIDVDG CAS-L40 AIEHDG CAS-L41 AIEIDG CAS-L42 AIENDG CAS-43 AIEPDG CAS-44 AIEQDG CAS-45 AIESDG CAS-46 AIETDG CAS-47 AIEVDG CAS-48 AIFQGPID C03.007-rhinovirus picornain 3C AIGHDG CAS-49 AIGNDG CAS-L50 AIGPDG CAS-L51 AIGQDG CAS-52 AIGSDG CAS-53 AIGTDG CAS-54 AIPMSIPP M10.051-serralysin AISHDG CAS-L55 AISNDG CAS-L56 AISPDG CAS-57 AISQDG CAS-58 AISSDG CAS-59 AISTDG CAS-L60 AKQRAKRD S08.071-furin AKRQGLPV C03.007-rhinovirus picornain 3C AKRRAKRD S08.071-furin AKRRTKRD S08.071-furin ALAALAKK M11.001-gametolysin ALDIDG CAS-L61 ALDPDG CAS-62 ALDTDG CAS-63 ALDVDG CAS-L64 ALEIDG CAS-L65 ALEPDG CAS-L66 ALETDG CAS-67 ALEVDG CAS-68 ALFQGPLQ C03.001-poliovirus-type picornain
    [Show full text]
  • Yapsin 1 Immunoreactivity in A-Cells of Human Pancreatic Islets: Implications for the Processing of Human Proglucagon by Mammalian Aspartic Proteases
    181 Yapsin 1 immunoreactivity in a-cells of human pancreatic islets: implications for the processing of human proglucagon by mammalian aspartic proteases Niamh X Cawley*, Guida Portela-Gomes1,*, Hong Lou and Y Peng Loh Section on Cellular Neurobiology, Eunice Shriver Kennedy National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA 1Department of Gastroenterology, University of Lisbon, Lisbon, Portugal (Correspondence should be addressed to N X Cawley; Email: [email protected]) *(N X Cawley and G Portela-Gomes contributed equally to this work) Abstract Yapsin 1 is an aspartic protease from Saccharomyces cerevisiae immunoreactivity in the a-cells of human pancreatic islets. and belongs to a class of aspartic proteases that demonstrate No staining was observed in the b-ord-cells, indicating a specificity for basic amino acids. It is capable of processing specificity of the staining for glucagon-producing and not prohormone substrates at specific basic residue cleavage sites, insulin- or somatostatin-producing cells. Purified yapsin 1 similar to that of the prohormone convertases, to generate was also shown to process proglucagon into glucagon in vitro, bioactive peptide hormones. An antibody raised against demonstrating that the prototypical enzyme of this subclass of yapsin 1 was previously shown to immunostain endocrine enzymes can correctly process proglucagon to glucagon. cells of rat pituitary and brain as well as lysates from These findings suggest the existence of a yapsin 1-like enzyme bovine pituitary secretory granules demonstrating the exclusively in the a-cells of the islets of Langerhans in existence of yapsin 1-like aspartic proteases in mammalian humans, which may play a role in the production of glucagon endocrine tissues, potentially involved in peptide hormone in that tissue.
    [Show full text]
  • A Set of Aspartyl Proteasedeficient Strains for Improved
    RESEARCH ARTICLE A set ofaspartyl protease-de¢cient strains for improved expression of heterologous proteins in Kluyveromyces lactis Mehul B. Ganatra1, Saulius Vainauskas1, Julia M. Hong1, Troy E. Taylor2, John-Paul M. Denson2, Dominic Esposito2, Jeremiah D. Read1, Hana Schmeisser3, Kathryn C. Zoon3, James L. Hartley2 & Christopher H. Taron1 1Division of Gene Expression, New England Biolabs, Ipswich, MA, USA; 2Protein Expression Laboratory, Advanced Technology Program, SAIC-Frederick Inc., National Cancer Institute at Frederick, Frederick, MD, USA; and 3The Cytokine Biology Section, The Division of Intramural Research, NIAID, NIH, Bethesda, MD, USA Correspondence: Christopher H. Taron, Abstract Division of Gene Expression, New England Biolabs, 240 County Road, Ipswich, MA Secretion of recombinant proteins is a common strategy for heterologous protein 01938-2723, USA. Tel.: 11 978 927 5054; expression using the yeast Kluyveromyces lactis. However, a common problem is fax: 11 978 921 1350; degradation of a target recombinant protein by secretory pathway aspartyl e-mail: [email protected] proteases. In this study, we identified five putative pfam00026 aspartyl proteases encoded by the K. lactis genome. A set of selectable marker-free protease deletion Received 12 May 2010; revised 5 October 2010; mutants was constructed in the prototrophic K. lactis GG799 industrial expression accepted 31 October 2010. strain background using a PCR-based dominant marker recycling method based Final version published online 17 December on the Aspergillus nidulans acetamidase gene (amdS). Each mutant was assessed for 2010. its secretion of protease activity, its health and growth characteristics, and its DOI:10.1111/j.1567-1364.2010.00703.x ability to efficiently produce heterologous proteins.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur Et Al
    US 2012026.6329A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur et al. (43) Pub. Date: Oct. 18, 2012 (54) NUCLEICACIDS AND PROTEINS AND CI2N 9/10 (2006.01) METHODS FOR MAKING AND USING THEMI CI2N 9/24 (2006.01) CI2N 9/02 (2006.01) (75) Inventors: Eric J. Mathur, Carlsbad, CA CI2N 9/06 (2006.01) (US); Cathy Chang, San Marcos, CI2P 2L/02 (2006.01) CA (US) CI2O I/04 (2006.01) CI2N 9/96 (2006.01) (73) Assignee: BP Corporation North America CI2N 5/82 (2006.01) Inc., Houston, TX (US) CI2N 15/53 (2006.01) CI2N IS/54 (2006.01) CI2N 15/57 2006.O1 (22) Filed: Feb. 20, 2012 CI2N IS/60 308: Related U.S. Application Data EN f :08: (62) Division of application No. 1 1/817,403, filed on May AOIH 5/00 (2006.01) 7, 2008, now Pat. No. 8,119,385, filed as application AOIH 5/10 (2006.01) No. PCT/US2006/007642 on Mar. 3, 2006. C07K I4/00 (2006.01) CI2N IS/II (2006.01) (60) Provisional application No. 60/658,984, filed on Mar. AOIH I/06 (2006.01) 4, 2005. CI2N 15/63 (2006.01) Publication Classification (52) U.S. Cl. ................... 800/293; 435/320.1; 435/252.3: 435/325; 435/254.11: 435/254.2:435/348; (51) Int. Cl. 435/419; 435/195; 435/196; 435/198: 435/233; CI2N 15/52 (2006.01) 435/201:435/232; 435/208; 435/227; 435/193; CI2N 15/85 (2006.01) 435/200; 435/189: 435/191: 435/69.1; 435/34; CI2N 5/86 (2006.01) 435/188:536/23.2; 435/468; 800/298; 800/320; CI2N 15/867 (2006.01) 800/317.2: 800/317.4: 800/320.3: 800/306; CI2N 5/864 (2006.01) 800/312 800/320.2: 800/317.3; 800/322; CI2N 5/8 (2006.01) 800/320.1; 530/350, 536/23.1: 800/278; 800/294 CI2N I/2 (2006.01) CI2N 5/10 (2006.01) (57) ABSTRACT CI2N L/15 (2006.01) CI2N I/19 (2006.01) The invention provides polypeptides, including enzymes, CI2N 9/14 (2006.01) structural proteins and binding proteins, polynucleotides CI2N 9/16 (2006.01) encoding these polypeptides, and methods of making and CI2N 9/20 (2006.01) using these polynucleotides and polypeptides.
    [Show full text]